GB0112687D0 - Pharmaceutical use of secreted bacterial effector proteins - Google Patents

Pharmaceutical use of secreted bacterial effector proteins

Info

Publication number
GB0112687D0
GB0112687D0 GBGB0112687.9A GB0112687A GB0112687D0 GB 0112687 D0 GB0112687 D0 GB 0112687D0 GB 0112687 A GB0112687 A GB 0112687A GB 0112687 D0 GB0112687 D0 GB 0112687D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical use
effector proteins
bacterial effector
secreted bacterial
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0112687.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbiological Research Authority
Original Assignee
Microbiological Research Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbiological Research Authority filed Critical Microbiological Research Authority
Priority to GBGB0112687.9A priority Critical patent/GB0112687D0/en
Publication of GB0112687D0 publication Critical patent/GB0112687D0/en
Priority to CNB028105052A priority patent/CN100439394C/zh
Priority to EP02726319A priority patent/EP1390400A2/en
Priority to PCT/GB2002/002384 priority patent/WO2002096467A2/en
Priority to JP2002592975A priority patent/JP2004533250A/ja
Priority to AU2002256803A priority patent/AU2002256803B2/en
Priority to CA002448963A priority patent/CA2448963A1/en
Priority to US10/478,516 priority patent/US20040208889A1/en
Priority to JP2009202601A priority patent/JP2009286794A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0112687.9A 2001-05-24 2001-05-24 Pharmaceutical use of secreted bacterial effector proteins Ceased GB0112687D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0112687.9A GB0112687D0 (en) 2001-05-24 2001-05-24 Pharmaceutical use of secreted bacterial effector proteins
CNB028105052A CN100439394C (zh) 2001-05-24 2002-05-21 分泌性细菌效应蛋白的药物用途
EP02726319A EP1390400A2 (en) 2001-05-24 2002-05-21 Pharmaceutical use for secreted bacterial effector proteins
PCT/GB2002/002384 WO2002096467A2 (en) 2001-05-24 2002-05-21 Pharmaceutical use for secreted bacterial effector proteins
JP2002592975A JP2004533250A (ja) 2001-05-24 2002-05-21 分泌された細菌エフェクタータンパク質の薬学的使用
AU2002256803A AU2002256803B2 (en) 2001-05-24 2002-05-21 Pharmaceutical use for secreted bacterial effector proteins
CA002448963A CA2448963A1 (en) 2001-05-24 2002-05-21 Pharmaceutical use for secreted bacterial effector proteins
US10/478,516 US20040208889A1 (en) 2001-05-24 2002-05-21 Pharmaceutical use for secreted bacterial effector proteins
JP2009202601A JP2009286794A (ja) 2001-05-24 2009-09-02 分泌された細菌エフェクタータンパク質の薬学的使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0112687.9A GB0112687D0 (en) 2001-05-24 2001-05-24 Pharmaceutical use of secreted bacterial effector proteins

Publications (1)

Publication Number Publication Date
GB0112687D0 true GB0112687D0 (en) 2001-07-18

Family

ID=9915236

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0112687.9A Ceased GB0112687D0 (en) 2001-05-24 2001-05-24 Pharmaceutical use of secreted bacterial effector proteins

Country Status (8)

Country Link
US (1) US20040208889A1 (cg-RX-API-DMAC7.html)
EP (1) EP1390400A2 (cg-RX-API-DMAC7.html)
JP (2) JP2004533250A (cg-RX-API-DMAC7.html)
CN (1) CN100439394C (cg-RX-API-DMAC7.html)
AU (1) AU2002256803B2 (cg-RX-API-DMAC7.html)
CA (1) CA2448963A1 (cg-RX-API-DMAC7.html)
GB (1) GB0112687D0 (cg-RX-API-DMAC7.html)
WO (1) WO2002096467A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
DE102004035606A1 (de) * 2004-07-22 2006-03-30 Biotecon Therapeutics Gmbh Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit
US20060068469A1 (en) * 2004-08-17 2006-03-30 Research Development Foundation Bacterial vector systems
WO2006023332A2 (en) * 2004-08-20 2006-03-02 Children's Medical Center Corporation Method for the inhibition of angiogenesis or cancer using protective antigen related molecules
US8092806B2 (en) * 2005-04-11 2012-01-10 Yeda Research And Development Co. Ltd. Chimeric proteins, their preparation and pharmaceutical compositions containing them
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
WO2011117259A1 (en) * 2010-03-23 2011-09-29 Imba - Institut Für Molekulare Biotechnologie Gmbh Methods for identifying inhibitors of the type iii secretion system
WO2012054693A1 (en) * 2010-10-22 2012-04-26 Trudeau Institute Uses of yersinia yope peptide, gene, and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells
KR101839496B1 (ko) 2011-06-01 2018-03-19 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
KR20180021703A (ko) * 2015-05-15 2018-03-05 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 선택된 세포로 분자를 전달하도록 개조된 조작된 클로스트리디움 보툴리눔 독소
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
US20210054033A1 (en) 2018-01-25 2021-02-25 The Wistar Institute Of Anatomy And Biology Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
WO2022087856A1 (zh) * 2020-10-26 2022-05-05 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498192A2 (fr) * 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
ATE25197T1 (de) * 1982-05-12 1987-02-15 Harvard College Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
DE69511860T2 (de) * 1994-05-31 2000-02-10 Allergan, Inc. Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
SE9702191D0 (sv) * 1997-06-09 1997-06-09 Sven Pettersson Coposition and methods for the treatment of inflammatory dideases
US5965381A (en) 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
WO2001019393A1 (en) * 1999-09-13 2001-03-22 Cornell Research Foundation, Inc. Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems

Also Published As

Publication number Publication date
WO2002096467A2 (en) 2002-12-05
US20040208889A1 (en) 2004-10-21
EP1390400A2 (en) 2004-02-25
CN100439394C (zh) 2008-12-03
AU2002256803B2 (en) 2006-11-09
CA2448963A1 (en) 2002-12-05
CN1531549A (zh) 2004-09-22
WO2002096467A3 (en) 2003-04-10
JP2004533250A (ja) 2004-11-04
JP2009286794A (ja) 2009-12-10

Similar Documents

Publication Publication Date Title
AU2002326293A1 (en) Human secreted proteins
AU2002321999A1 (en) Human secreted proteins
AU2002361452A1 (en) Secreted proteins
AU2001227833A1 (en) 71 human secreted proteins
AU2002232596A1 (en) Secreted human proteins
AU2002353227A1 (en) Secreted proteins
AU2002342010A1 (en) Secreted proteins
AU2002354803A1 (en) Secreted proteins
AU2003301843A1 (en) 157 human secreted proteins
AU2002255733A1 (en) Secreted proteins
AU2002252700A1 (en) Secreted proteins
AU2001294719A1 (en) Secreted human proteins
EP1370651A4 (en) 70 HUMAN SECRETED PROTEINS
AU2002365153A1 (en) 41 human secreted proteins
AU2002327533A1 (en) Secreted proteins
AU2002258657A1 (en) Secreted proteins
AU2001229507A1 (en) 21 human secreted proteins
AU2001283327A1 (en) 8 human secreted proteins
AU2002327176A1 (en) 20 human secreted proteins
AU2001229503A1 (en) 17 human secreted proteins
AU2002246998A1 (en) 50 human secreted proteins
AU2001229563A1 (en) 21 human secreted proteins
AU2002348034A1 (en) 16 human secreted proteins
AU2002360333A1 (en) Human angiomotin-like protein 1
AU2003211137A1 (en) 20 human secreted proteins

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)